Amalgamated Bank lessened its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 9.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,749 shares of the medical device company’s stock after selling 2,120 shares during the quarter. Amalgamated Bank’s holdings in Tandem Diabetes Care were worth $796,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. ORG Partners LLC bought a new stake in Tandem Diabetes Care during the second quarter worth approximately $31,000. Headlands Technologies LLC purchased a new position in Tandem Diabetes Care during the first quarter valued at approximately $35,000. MCF Advisors LLC lifted its stake in shares of Tandem Diabetes Care by 79.3% during the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock worth $36,000 after purchasing an additional 445 shares during the last quarter. Daiwa Securities Group Inc. purchased a new position in shares of Tandem Diabetes Care in the 2nd quarter worth approximately $86,000. Finally, Signaturefd LLC lifted its holdings in shares of Tandem Diabetes Care by 29.2% during the 2nd quarter. Signaturefd LLC now owns 2,307 shares of the medical device company’s stock valued at $93,000 after purchasing an additional 522 shares during the last quarter.
Tandem Diabetes Care Trading Down 3.7 %
Tandem Diabetes Care stock opened at $42.45 on Friday. The firm’s 50 day moving average price is $42.18 and its two-hundred day moving average price is $41.10. The firm has a market cap of $2.78 billion, a price-to-earnings ratio of -19.56 and a beta of 1.32. Tandem Diabetes Care, Inc. has a 1 year low of $13.82 and a 1 year high of $53.69. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.38 and a current ratio of 3.05.
Analyst Upgrades and Downgrades
TNDM has been the topic of several research analyst reports. Barclays boosted their target price on shares of Tandem Diabetes Care from $55.00 to $58.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. UBS Group upgraded Tandem Diabetes Care to a “hold” rating in a report on Friday, August 2nd. Morgan Stanley reissued an “equal weight” rating and set a $45.00 price objective on shares of Tandem Diabetes Care in a research note on Monday, September 23rd. Canaccord Genuity Group started coverage on Tandem Diabetes Care in a research report on Thursday, August 8th. They issued a “buy” rating and a $57.00 target price for the company. Finally, Robert W. Baird upped their target price on shares of Tandem Diabetes Care from $36.00 to $39.00 and gave the stock a “neutral” rating in a research note on Friday, August 2nd. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $54.36.
Get Our Latest Stock Analysis on Tandem Diabetes Care
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
Featured Stories
- Five stocks we like better than Tandem Diabetes Care
- What Are the FAANG Stocks and Are They Good Investments?
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- ESG Stocks, What Investors Should Know
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- How to Calculate Stock Profit
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.